4H-Pyrido(1,2-a)pyrimidin-4-one
![]() | |
| Names | |
|---|---|
| IUPAC name
pyrido[1,2-a]pyrimidin-4-one | |
| Other names
4H-pyrido(1,2-a)pyrimidin-4-one | |
| Identifiers | |
3D model (JSmol) |
|
| ChEMBL | |
| ChemSpider | |
| EC Number |
|
PubChem CID |
|
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C8H6N2O | |
| Molar mass | 146.15 g/mol |
| Appearance | Solid |
| Hazards | |
| GHS labelling:[1] | |
![]() | |
| Warning | |
| H302, H312, H332 | |
| P261, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, P501 | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references | |
4H-Pyrido[1,2-a]pyrimidin-4-one is a heterocyclic compound consisting of a pyridine ring fused to a pyrimidine ring through a shared nitrogen atom, with a ketone at the 4-position. It is the parent compound of the pyrido[1,2-a]pyrimidine ring system, a privileged scaffold in medicinal chemistry whose derivatives have been investigated across multiple therapeutic areas including cardiovascular, antiallergic, antiasthmatic, and antiparasitic research.
History
The pyrido[1,2-a]pyrimidine ring system was first described in 1911 by Palazzo and Tamburini, who assigned an incorrect structure — the 2-oxo isomer — to the product obtained from 2-aminopyridine and ethyl acetoacetate.[2] This incorrect assignment was repeated independently by Seide (1925), Crippa and Scevola (1937), and Khitrik (1939), and stood uncorrected for nearly forty years across four research groups.
The correct structure — the 4-oxo isomer — was established by Antaki and Petrow in 1951 by an independent synthesis: the reaction of 2-bromopyridine with ethyl β-aminocrotonate, a route entirely unconnected to the original preparation.[3] This assignment was confirmed independently by Adams and Pachter in 1952.[4] Shur and Israelstam, writing in the Journal of Organic Chemistry in 1968, credited the correction explicitly in the running text of their paper.[5]
The chemistry of the ring system was extended in 1958 by Antaki, working from the Research Institute for Tropical Medicine, Cairo, who synthesised a series of 3-substituted derivatives — including 3-acetyl and 3-cyano analogues — via condensation of ethyl ethoxymethyleneacetoacetate and cyanoacetate with 2-aminopyridine and its methyl derivatives. The 1958 study provided the first systematic ultraviolet spectroscopic characterisation of the pyrido[1,2-a]pyrimidine series, enabling structural distinction between bicyclic isomers by UV absorption.[6]
The 1958 paper is cited as the primary reference (Reference 1a) for the reagent ethyl ethoxymethyleneacetoacetate in the Encyclopedia of Reagents for Organic Synthesis (e-EROS), published by Wiley.[7]
The canonical review of the chemistry of pyrido[1,2-a]pyrimidines was published by Hermecz and Mészáros in Advances in Heterocyclic Chemistry in 1983, covering synthesis, spectroscopy, and biological activity across the compound class.[8]
Pharmaceutical applications
The pyrido[1,2-a]pyrimidin-4-one scaffold has been cited as prior art in pharmaceutical patent research across multiple therapeutic areas. Pfizer cited both the 1951 and 1958 papers directly in patent specifications related to cardiovascular and antiasthmatic research, noting that the 1958 compound demonstrated antischistosomal action.[9]
Derivatives of the pyrido[1,2-a]pyrimidine scaffold have been reported to exhibit tranquiliser, antiallergic, antiulcerative, antiasthmatic, and bronchodilator activity, as well as analgesic activity and human platelet aggregation inhibitory properties.[10]: 230
The scaffold is structurally related to several pharmaceutical compounds including risperidone and paliperidone, whose synthesis employs tetrahydro derivatives of the pyrido[1,2-a]pyrimidine ring system.
References
- ↑ PubChem. "4H-Pyrido[1,2-a]pyrimidin-4-one". pubchem.ncbi.nlm.nih.gov. Retrieved 2026-04-26.
- ↑ F. C. Palazzo and A. Tamburini, Atti Accad. Naz. Lincei [5] 20 (1911): 37.
- ↑ H. Antaki and V. Petrow, "New Syntheses of Heterocyclic Compounds. Part XII." Journal of the Chemical Society (1951): 551–555.
- ↑ R. Adams and I. Pachter, J. Am. Chem. Soc. 74 (1952): 5491.
- ↑ M. Shur and S. S. Israelstam, J. Org. Chem. 33(8) (1968): 3015.
- ↑ H. Antaki, "The Reaction of α-Ethoxymethylenecarboxylic Esters with Some Cyclic Amidines." Journal of the American Chemical Society 80 (1958): 3066–3069. DOI: 10.1021/ja01545a041
- ↑ R. M. Böhme, "Ethyl Ethoxymethyleneacetoacetate." Encyclopedia of Reagents for Organic Synthesis. Wiley, 2001. DOI: 10.1002/047084289X.re082
- ↑ I. Hermecz and Z. Mészáros, "Chemistry of Pyrido[1,2-a]pyrimidines." Advances in Heterocyclic Chemistry 33 (1983): 241–330.
- ↑ Pfizer Inc. US Patent 4,041,163 (1977); US Patent 4,066,766 (1978).
- ↑ Bonacorso, Helio G.; Righi, Fernando J.; Rodrigues, Isadora R.; Cechinel, Cleber A.; Costa, Michelle B.; Wastowski, Arci D.; Martins, Marcos A. P.; Zanatta, Nilo (January 2006). "New efficient approach for the synthesis of 2‐alkyl(aryl) substituted 4H‐pyrido[1,2‐a]pyrimidin‐4‐ones". Journal of Heterocyclic Chemistry. 43 (1): 229–233. doi:10.1002/jhet.5570430136.
Bibliography
- Antaki, H.; Petrow, V. "New Syntheses of Heterocyclic Compounds. Part XII." Journal of the Chemical Society 1951, 551–555.
- Antaki, H. "The Reaction of α-Ethoxymethylenecarboxylic Esters with Some Cyclic Amidines." Journal of the American Chemical Society 1958, 80, 3066–3069. DOI: 10.1021/ja01545a041
- Hermecz, I.; Mészáros, Z. "Chemistry of Pyrido[1,2-a]pyrimidines." Advances in Heterocyclic Chemistry 1983, 33, 241–330.
- Bonacorso, H. G. et al. "New Efficient Approach for the Synthesis of 2-Alkyl(aryl) Substituted 4H-Pyrido[1,2-a]pyrimidin-4-ones." Journal of Heterocyclic Chemistry 2006, 43, 229–233.
pyrimidin-4-one.svg.png)
